




QURIS-AI IMPACT REVIEW

2022-2023

Contents

Letter from the CEO and Quris-AI Founder, Isaac Bentwhich	4
Introduction to Quris-AI	5
Quris-AI in a nutshell	5
Technology Edge	5
Who We Are	6
Our Core Values	7
Quris-AI's Vision	7
Our ESG Leadership	8
Our UNSDG Impact Model	8
Our UNSDG Impact	9
Commitment to Patients & Community	16
Safe, Accessible and Affordable Medicines	17
Animal Testing	17
Patient Safety	17
Clinical Prediction	18
Drug Development Focusing on Rare Diseases	18
Genetic Diversity	19
Collaboration & Partnership	19
Our People and Culture	20
Our People and Culture	21
Our People Targets for 2023 and 2024	21
Employee Development and Training	23
Employee Engagement	24
Work-life Balance	24
Belonging & Inclusion	25
Employee Health & Safety	25

Environment	26
Our Environmental Management	27
Energy management	27
Waste management	28
Water use	28
Governance & Ethics	29
Ethical Governance	30
Our ESG Policies	30
Conflict Minerals	31
Ethical Marketing Practices	31
About this Review	32
About this Review	33
Statement from Good Vision	33
SASB Index	34



The background features a complex network diagram with white lines and nodes on a dark blue-grey gradient. Large, semi-transparent letters 'U' and 'R' are visible in the upper right. A white horizontal line is positioned above the main title.

INTRODUCTION

Letter from the CEO and Founder, Isaac Bentwhich

At Quris-AI, we are passionate about making the world a better place through scientific excellence and the unwavering pursuit of ground-breaking, innovative solutions. In an ever-changing world, we have a responsibility to advance tomorrow's healthcare by leveraging innovative solutions that contribute to a better future for all.

I am proud to share with you our inaugural Impact Review, which highlights some of our latest milestones, as well as the best practices and operations performed by our team. We strive to conduct business responsibly, in order to maximize our societal impact and drive business growth.

This past year, Quris-AI successfully achieved numerous significant collaboration and relationship building milestones integral to our success. We are proud to have established a research partnership with the Mohamed Bin Zayed University of Artificial Intelligence (MBZUAI) in Abu Dhabi. Additionally, we have forged an agreement with Merck KGaA, a leading global pharmaceutical company. These partnerships open the doors to new research exploration and future relationships with pharmaceutical companies that will allow us to continue to assess Quris-AI's BioAI safety prediction platform.

This year also marked a historic development for the pharmaceutical sector, as our perspective on the importance of innovating the drug development process for the needs of the 21st century was reflected in the landmark FDA Modernization Act 2.0, which has eliminated the antiquated reliance on animal testing.

As an international company focused on sustaining human health and disrupting the inefficiencies of the pharmaceutical industry, creating a positive impact is essential to our business strategy. Evaluating our impact through the lens of the United Nations' Sustainable Development Goals (UNSDGs) aligns with our values and company approach, allowing us to assess our current and potential impact holistically. The UNSDGs emphasize the interconnectedness between improving health and education, reducing inequality, spurring economic growth, and preserving planetary resources. They also reflect the beneficial ripple effect that potential disruptions in the bio-AI revolution can have on areas beyond human health, including responsible economic growth (SDG8), reducing inequalities (SDG10), responsible resource consumption and production (SDG12) and more.

Beyond making a positive impact through our cutting-edge product, it is essential for us to track, manage, and improve the company's environmental, social, and governance practices. We recognize strong ESG principles strengthen our relationship to the community, employees, and partners, making our business more resilient overall. While we are in the early stages of developing our ESG business approach, at our core, we are dedicated to creating a positive work environment, encouraging diversity, and reducing our environmental footprint. Through measuring, learning, and better understanding our impact, we intend to set a comprehensive ESG strategy in the coming year, with long-term targets and initiatives in all material areas.

Quris-AI is at the forefront of a revolution that has tremendous potential to improve health and well-being around the world. We will continue to show our leadership in the field by upholding our values and operating with integrity and professionalism. I hope that you enjoy learning more about our impacts and initiatives throughout this review.

Sincerely,

Isaac Bentwhich

CEO and Founder



QURIS-AI in a nutshell



Founded 2020,
Boston-Tel-Aviv



Public Collaborations:
MERCK NYSCF
BeyondBio



Team:
45 Employees, 30% Bio,
50% AI/Comp




29 Patents: BIO-AI,
Nano-sensing &
Drug Substances



Stellar Team,
Tech, Investors



Technology Edge



Who We Are

Quris-AI is the world's first Bio-AI Clinical Prediction Platform that better predicts which drug candidates will safely work in humans, thus dramatically reducing drug development cost and time while minimizing animal testing.

As an artificial intelligence pioneer, Quris-AI is revolutionizing the drug development process with our innovative Patients-on-a-Chip platform that generates a vast proprietary dataset. Our Bio-AI Clinical Prediction Platform harnesses powerful AI, training the system on hundreds of stem cell-derived Patients-on-a-Chip that reflect an exceptionally diverse genomic range. Our highly scalable platform enhances predictions for drug candidates' safety in humans, bypassing the enormous expenses associated with unsuccessful clinical trials.

Together, we tackle life's toughest AI challenges

Our team consists of leading scientists and strategic investors, actively preparing for clinical testing with our first AI-based drug. Hailing from various disciplines, we share a common vision to dramatically transform drug development for the benefit of all. We take pride in being guided by visionary pioneers from multiple domains, leveraging cutting-edge machine learning, engineering, and biology. Together, we are elevating drug development to unprecedented heights.

One platform.

Three synergistic revenue engines.

1

PHARMA ALLIANCES

Enabling pharma companies to develop safe drugs faster and reduce animal testing.

2

DRUG PIPELINE

Acquiring drug candidate assets that our platform predicts will pass phase-I, thereby tripling their value (an 'arbitrage-like' approach)

3

PERSONAL SAFETY

A revolutionary service empowering consumers to assess which drugs are safe for them personally. This creates and dominates a new business domain of personalized drug safety.

Our Core Values



COLLABORATION

Uniting our best thinking through teamwork



PLAYFUL LEARNING

Fostering a culture of curiosity that embraces failure as an integral part of the learning and innovation process



INNOVATION

Continuously challenging ourselves to improve



MAKING A DIFFERENCE

Supporting our communities with transformative technology that revolutionizes health



PERSONAL DEVELOPMENT


Inspiring employees to be creative and take risks



DIVERSITY, EQUITY AND INCLUSION

Valuing and respecting our differences to achieve our collective goals

Quris-AI's Vision




Our vision
is to re-imagine drug
development to
deliver safe, reliable
and affordable drugs
for all

We aim to break traditional boundaries in the pharmaceutical industry by embracing genetic diversity and ensuring universal access to necessary medicines.

Our ESG Leadership

To track our progress towards sustainability goals, we have integrated ESG practices into our governance structure. Starting in 2023, our ESG leadership team will convene quarterly to supervise and advance our sustainability agenda.



Our UNSDG Impact Model

At Quris-AI, we seek to advance the SDG's and contribute to a sustainable future for all.



OUR UNSDG IMPACT

3 Good health



ENSURE HEALTHY LIVES AND PROMOTE WELL-BEING FOR ALL AT ALL AGES

Sub-Goal 3.4 By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being

Sub-Goal 3.8 Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all

At Quris-AI better health and better medicine is at our core. We are committed to promoting good health and well-being through our technology innovation and in our own operations;

- Health inequality remains one of the primary public health and healthcare challenges in the 21st century. Health disparities are not restricted to care delivery; they can also stem from the structure of clinical trials. **Clinical trials often fail to represent the general population, typically enrolling Caucasian male patients.** Quris-AI's patient-on-chip technology addresses these demographic disparity issues by prioritizing genetic diversity throughout the research process.
- We concentrate our drug development partnerships and research on novel medicine development for rare diseases and genetic disorders. Due to the lack of market scale, these illnesses are often viewed as high-risk and not a worthwhile investment within the pharmaceutical industry, thus reducing the likelihood of necessary treatments or drugs being developed. The tremendous potential of our platform to de-risk and significantly reduce drug development time is exemplified by our preparation for clinical testing of our first drug, developed with our Bio-AI Clinical Prediction Platform targeting Fragile-X Syndrome.
- Internally, **as a company committed to safeguarding our employees' physical, emotional, and financial well-being, health and well-being are closely integrated into our human capital strategy.** At Quris-AI, we ensure employee recruitment, training, and development are executed sustainably by valuing each employee's skills and needs.

At Quris-AI, we are dedicated to improving people's lives by actively pursuing genetic diversity that delivers safe, effective, and affordable medicine.



1 Ending poverty



END POVERTY IN ALL ITS FORMS EVERYWHERE

Sub-Goal 1.4 By 2030, ensure that all men and women, in particular the poor and the vulnerable, have equal rights to economic resources, as well as access to basic services ... appropriate new technology and financial services, including microfinance

Poverty is both a cause and consequence of poor health. It can increase the risk of poor health while also trapping individuals and communities in poverty. Marginalized and vulnerable populations often suffer most from this cycle due to financial and accessibility barriers preventing access to proper treatment.

At Quris-AI, we strive to improve access to healthcare services, including medications and prescription drugs. **Our technology offers an affordable and effective alternative to traditional drug development, enabling pharmaceutical companies to create safe drugs at reduced costs.** This significantly lowers the drug development expenses and reduces pressure to recoup costs during the limited patent period, making medicines more accessible at lower prices. Ultimately, this alleviates medically related financial stress on individuals and communities. By leveraging our AI-based platform to identify effective drugs, Quris-AI is dedicated to increasing access to safe medicines.

Healthcare spending has significant implication on poverty:


1.125 Billion – Global population with impoverishing health at their relative poverty line

calculated by the WHO



Medical expenses were the largest contributor to increasing the number of individuals in poverty

US Census Bureau, 2018



5 Gender equality

ACHIEVE GENDER EQUALITY AND EMPOWER ALL WOMEN AND GIRLS

Sub-Goal 5.5 Ensure women's full and effective participation and equal opportunities for leadership at all levels of decision-making in political, economic and public life

We operate under the principle of treating each employee fairly and equitably. Our diversity, equity, and inclusion (DEI) efforts span from recruitment to ensuring equal opportunities for women in all positions. We continuously measure and evaluate gender and diversity in our offices and plan to set gender diversity KPIs by the end of 2023, aligned with our fast-growing team's needs.

We aim to improve gender equality in clinical trials by increasing female representation in test groups and focusing on treatments for women's health issues. Traditionally, women have been underrepresented in clinical trials and their health issues overlooked due to gender bias. Quris-AI ensures equal opportunities for women through organoids that eliminate the need for human subjects in clinical trials.

9

BUILD RESILIENT INFRASTRUCTURE, PROMOTE INCLUSIVE AND SUSTAINABLE INDUSTRIALIZATION AND FOSTER INNOVATION

Sub-Goal 9.5 Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending

At Quris-AI, we are pioneers in AI drug safety and development. Our scientific innovation tackles one of the most significant AI challenges of our time: predicting which drug candidates will be effective. By transforming the pharmaceutical industry's technological capabilities at the intersection of cutting-edge patient-on-chip and machine learning technology, we have devised a novel approach to developing medicines that prioritizes efficiency. Our team members hail from diverse disciplines, working in domains such as machine learning, engineering, and biology. Quris-AI is expanding its R&D-focused workforce as we scale up in the UAE, Japan, EU, and Singapore.

10 Reducing inequality



REDUCE INEQUALITY WITHIN AND AMONG COUNTRIES

Sub-Goal 10.2 By 2030, empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status

Quris-AI is committed to support the development of safer, affordable and more personalized drugs for all. To that end, Quris-AI is engaged with Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) to develop a world-class Bio-AI center in Abu Dhabi. The state-of-the-art facility will support the development of personalized medications, tailored specifically to the diverse populations of the MENA region.

The collaboration will establish a center of excellence in Bio-AI in Abu Dhabi, which will accelerate the development of safer, and more highly personalized medications.

Quris-AI is planning to establish similar centers in the EU, Japan, Singapore, US and South Africa.





ENSURE SUSTAINABLE CONSUMPTION AND PRODUCTION PATTERNS

Sub-Goal 12.2 By 2030, achieve the sustainable management and efficient use of natural resources

Sub-Goal 12.5 By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse


Sub-Goal 12.6 Encourage companies, especially large and transnational companies, to adopt sustainable practices and to integrate sustainability information into their reporting cycle

Quris-AI acknowledges the pharmaceutical industry's significant environmental impacts, including greenhouse gas emissions and water pollution. Achieving sustainable management within the healthcare sector requires maximizing resource efficiency. Our AI-powered platform enables the development of safer drugs faster, significantly reducing time to market and the associated resource inputs. Quris-AI not only enhances the value of the drug industry but also promotes sustainable management and efficient use of natural resources.

Presently, drug development is often ineffective, with 9 out of 10 drugs entering clinical trials after animal testing eventually failing. This results in a tremendous loss of resources and harm to millions of animals, despite billions of dollars invested and years of research and testing.

Only 1 of 276 potential drugs completes the entire process from preclinical to the final stage, an efficiency rate of 0.003%.

of potential drugs developed in 10 years



Drug Safety Failures Cost Pharma Companies \$18B/yr

Other AI companies do not solve this



PROMOTE PEACEFUL AND INCLUSIVE SOCIETIES FOR SUSTAINABLE DEVELOPMENT, PROVIDE ACCESS TO JUSTICE FOR ALL AND BUILD EFFECTIVE, ACCOUNTABLE, AND INCLUSIVE INSTITUTIONS AT ALL LEVELS

Health and peace are intimately interconnected as key pillars of sustainable development. The Middle East region faces significant challenges, including deep-rooted conflicts and inequalities. At Quris-AI, we actively strive to achieve peaceful societies through our cooperation with the United Arab Emirates (UAE). Our new bio-AI center in Abu Dhabi at the Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) exemplifies Quris-AI's commitment to fostering harmonious relationships with our neighbors. Collaborating with the UAE positions Quris-AI as an active partner in promoting inclusion and regional peace in the Middle East.

17 Partnering to achieve the goals



STRENGTHEN THE MEANS OF IMPLEMENTATION AND REVITALIZE THE GLOBAL PARTNERSHIP FOR SUSTAINABLE DEVELOPMENT

Sub-Goal 17.6 Enhance North-South, South-South and triangular regional and international cooperation on and access to science, technology and innovation and enhance knowledge-sharing on mutually agreed terms, including through improved coordination among existing mechanisms, in particular at the United Nations level, and through a global technology facilitation mechanism

We believe regional and international cooperation is crucial for achieving sustainable and effective solutions. Quris-AI fosters knowledge sharing through our international offices and partnerships in the USA, UAE, and plans for further expansions in Europe and Asia. We recognize the importance of global cooperation and access to innovation, as it can lead to novel discoveries reaching broader demographics. At Quris-AI, we think big and aim to make a difference by working with diverse communities to develop health solutions for all.

**COMMITMENT
TO PATIENTS &
COMMUNITY**

Safe, Accessible and Affordable Medicines

Drug safety remains a major unaddressed issue. A staggering 92% of all drugs fail in clinical trials despite 'successfully' passing animal testing, costing pharmaceutical companies over 53 billion dollars annually. The inefficiency of drug development places a burden on the pharmaceutical industry due to the billions of dollars invested and years spent testing in laboratories, potentially resulting in a failed drug. Currently, no company or solution addresses this challenge: predicting which drug candidate will be safe in the human body and for whom.

Quris-AI is recognized as a pioneer in AI drug safety, uniquely addressing this market problem and opportunity.

“ Quris-AI is going to have a far greater impact on the pharmaceutical industry and world-health than anybody realizes ”

Henry McKinnel,
former Pfizer CEO

Animal Testing

In the pharmaceutical industry, drugs in development undergo testing on animals before proceeding to human trials. **The industry relies on hundreds of millions of animals for testing to advance to the next stage of drug development.** This process is not only inefficient but also costly. By eliminating the high costs and time spent on animal testing, our platform can expedite the delivery of safer, more effective drugs to the market while reducing animal suffering where it is not critical for safe and accurate drug development. Additionally, shortening the drug development cycle can significantly lower drug prices for patients.

The new US FDA Modernization Act 2.0, passed in 2023, eliminates the requirement for drug development to undergo animal testing when proven alternatives are utilized. This groundbreaking change ends an 84-year reliance on antiquated and ineffective animal testing, supporting our mission of providing affordable and effective drug development to our communities.

We evaluate the toxicity of chemicals associated with our product to assess environmental and human health and safety.

Patient Safety

By simulating millions of interactions between known drugs and miniaturized interconnected human organs on a chip (referred to as patients-on-chip), our platform can accurately predict new drug candidates' safety. 90% of drugs fail in clinical trials, with a substantial portion of failures due to safety concerns. Quris-AI's patients-on-chip, which currently comprises liver, blood-brain barrier, and brain (with heart and kidney coming soon), provides enhanced drug safety predictions as our BIO-AI model demonstrates accuracy in predicting metabolites, biomarkers, and microscopy.


Drugs that succeed in animal testing only triumph in human trials 8% of the time. Our platform not only supersedes the need for inefficient animal testing by replicating human physiology, but it also offers a cost-effective alternative to current drug development methodologies.

Clinical Prediction

Our Bio-AI Clinical Prediction Platform employs Patients-on-a-Chip to generate a vast proprietary dataset that is automated, highly predictive, and utilizes classification algorithms to train machine learning models. This process enables better prediction of drug candidates that will work safely in humans. **Our platform is exceptional in accurately predicting the safety and personalization of new drug candidates, enhancing accessibility for patients requiring specific medications.** This approach can revolutionize personalized medicine, informing individuals which medications to use and avoid based on their genetic makeup.

Drug Development Focusing on Rare Diseases

The remarkable potential of our platform to de-risk and significantly reduce drug development time is demonstrated by our preparation for clinical testing of our first drug developed with our Bio-AI Clinical Prediction Platform targeting Fragile-X Syndrome. Representing a \$200 million market, **Fragile-X Syndrome is the most prevalent inherited cause of autism and intellectual disabilities globally.** Until now, big pharma drugs have consistently failed to treat Fragile-X in clinical trials. **Our drug, grounded in multiple top-tier peer-reviewed publications, is the only one addressing the root cause of the disease and holds potential for a complete cure.**




Genetic Diversity

Our platform actively seeks genetic diversity to ensure safety for all. Pharmaceutical industry biases have resulted in unrepresentative samples of the population, excluding minorities and other groups from scientific research. Quris-AI addresses this issue by promoting greater genetic diversity in drug development.

By focusing on genetic diversity, we can conduct better science thus resulting in better medicine and treatment for our communities.

We persistently evaluate multidisciplinary and international efforts to enhance diverse community representation. We are actively sourcing genetic variability worldwide through our multinational offices and collaboration centers in Tel Aviv, Boston, and most recently, Abu Dhabi. Our new Abu Dhabi location reflects our commitment to increasing genetic diversity for the benefit of science. With enhanced diversity, medicine can become more accessible for individuals seeking specific treatments.

Drug Development Safety Bias



Drug safety is a personal question. The Pharma industry is developing drugs for the average person. Quris-AI takes a different approach that aims to develop patient-specific drugs.

Our partners:**MERCK****BeyondBio**

TEL AVIV UNIVERSITY
Pursuing the Unknown

NYSCF

**The New York
Stem Cell Foundation**

NEWSTEM**Collaboration & Partnership**

At Quris-AI, we believe collaboration is vital to performing great science and innovation. We are proud to work with international organizations and universities in order to combine our best thinking in the pursuit of taking drug development to the next level. Our dynamic partnerships with organizations such as the New York Stem Cell Foundation and Newstem are critical as they support our mission of bringing diverse, affordable, and efficient drug development to the market.

Our exclusive collaboration with the New York Stem Cell Foundation, the world leader in stem-cell automation, is very important to us. The NYSCF grants Quris-AI special access to hundreds of stem-cell lines which aids in our work to predict drug safety and promote diversity.

“As Quris-AI expands its collaborations with pharmaceutical companies, this will hopefully lead to new ways to find novel drugs that safely meet patients’ needs in the years ahead.”

Dr. Robert S. Langer, co-founder of Moderna

Our business partnership with pharmaceutical companies is core to both our business and our impact. Our partnership with Merck will allow them to assess candidates for clinical safety prediction using our Bio-AI platform. Merck KGaA is a global science and technology company with more than 60,000 employees in 66 countries. The company develops, manufactures and markets prescription drugs and specialty chemical products.

BeyondBio SCALE is a 9-month program dedicated to helping startups navigate the challenging journey from start-up to scale-up. An interdisciplinary team from AstraZeneca and our global partners - Accenture, AWS, Clalit Health Services will share world-class insights, expertise, resources, connections and guidance equipping your startup with the tools and business links to accelerate deployment at scale.

We collaborate with international universities including Tel Aviv University, the Hebrew University of Jerusalem, and the Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). Our collaboration with MBZUAI will establish a Bio-AI center in Abu Dhabi with the aim of accelerating safe and personalized drug development. Our subsidiary in Abu Dhabi provides MBZUAI students with increased opportunity in their field, whilst also supporting the development of personalized medications. In this case, genetic variability can be taken from the MENA region in order to tailor medicine needed for the community.

Quris-AI is similarly engaged in discussions on collaboration with other top pharma companies.

The background features a large, semi-transparent watermark of the word 'OUR' in a bold, sans-serif font. Overlaid on this are various network graphics, including a complex web of white lines and nodes on the right side, and several faint, overlapping circular patterns in shades of blue and grey. A thin white horizontal line is positioned above the main text.

OUR PEOPLE & CULTURE


Our People and Culture

At the heart of Quris-AI are our people. Together, we confront life's most formidable AI challenges. As a compact enterprise with 45 employees (as of the end of 2022), we devote special attention to each team member, fostering a healthy and inspiring work environment.

Our People Targets for 2023 and 2024


- Implement a company-wide annual employee feedback survey
- Initiate a mechanism to measure and track employee training hours, setting training KPIs
- Strengthen employee relationships between our Israel and the US office through company-wide events
- Establish gender diversity KPIs by the end of 2023, aligned with our rapidly expanding team's requirements.
- Launch employee volunteer days and volunteer opportunities

Employee Growth



Employee Gender Diversity

June 2023



Diversity in Roles

	Manager Role	Science & Technical Role
Male	10	20
Female	7	8

Employee Development and Training

As a dynamic and agile team, we prioritize employee growth and development, encouraging continuous learning through various methods. We adopt a personalized approach, motivating employees to collaborate with their managers to create learning plans for upskilling or acquiring new technical expertise. Additionally, we promote alternative learning opportunities such as conferences, webinars, and events. In 2023, we plan to implement a system to monitor and track employee training hours.

Our employees receive annual training in various areas, encompassing both hard and soft skill development. Training in 2022 included management, English professional proficiency, Excel program training, and more.

We continually assess our progress, incorporating lessons learned into our work. From the moment an employee joins us, we start building a culture of dialogue and feedback. Our comprehensive six-month onboarding process ensures new employees successfully integrate into the company. Managers support team members' growth and development through regular feedback and open dialogue. As we expand, we plan to further formalize our performance review process to provide employees with consistent insights into their performance and achievements.

Engaging with the AI Community during AI-Week



At Quris-AI, we recognize the importance of collaboration and constant learning to stay at the cutting edge of our industry. We actively seek opportunities to engage with the wider research and business community. This year, we were excited to participate in AI Week, the leading international conference for AI innovation, research, and application. Quris-AI CEO, Bentwich MD, and Shahar Harel, Head of AI, spoke at the event. Additionally, our entire AI team participated to showcase Quris-AI's innovative intersection between machine learning and biotechnology.

Employee Engagement

One of our core goals is to foster a work environment where employees can thrive. Strong employee relationships and engagement are key drivers of Quris-AI's success. To achieve this, we adhere to an open-door policy, encouraging informal feedback mechanisms and conducting annual anonymous surveys.

We listen and act upon employee feedback, striving to meet our team's needs. Our Israel office hosts bi-weekly happy hours, and our US branch organizes weekly team dinners. These events allow us to share company updates and enable team members to educate their colleagues about their areas of work. We also host various company events to celebrate holidays, family gatherings, employee birthdays, and other occasions. These regular, fun, and educational events help build camaraderie, broaden understanding of the work performed across the company, and facilitate company-wide dialogue and feedback.

As a rapidly developing startup, we are still in the early stages of creating our community engagement and volunteering activities. Nevertheless, we are committed to accelerating social change by supporting communities. In 2023, we plan to initiate volunteering days for employees.

Our employee engagement and activities include:

- Quarterly company-wide events
- Happy Hour and team dinners
- Annual company trip
- Weekly yoga class
- Welcome gift to all new employees
- Office Ice-cream machine- Anyday.

Work-life Balance

At Quris-AI, we promote an optimal balance between work and personal life. We believe work-life balance not only enhances our employees' personal lives but also encourages self-improvement, aligning with our social values. We offer our employees flexibility in work hours and location through a hybrid work model, allowing them to work in the most effective way for their needs.

We encourage our employees to maintain a healthy lifestyle and stay active by offering weekly yoga classes and vouchers for workout options of their choice.

Belonging & Inclusion

At Quri-AI, we champion diversity, equity, and inclusion throughout our workforce, leadership, product and service development, and within our industry. We maintain a zero-tolerance policy towards any form of discrimination, and this commitment begins even before an individual becomes part of our team. Our Non-discrimination and DEI policy are conveyed to all employees and publicly accessible on our website here. As our team expands globally, we continually monitor and update our diversity metrics to ensure racial and gender equality.

Our latest office in Abu Dhabi exemplifies our social objectives. Collaborating with the AI University in Abu Dhabi not only deepens our biotech expertise but also enables our employees to share their professional and personal experiences with individuals from diverse cultural backgrounds.

Employee Health & Safety

The health and safety of our people is always paramount at Quri-AI. We strive for an accident- and injury-free workplace, closely adhering to all relevant safety regulations for our business processes. In 2021 and 2022, we recorded zero work-related safety incidents or injuries.

We are committed to ensuring the health and safety of all our members throughout their work. Each laboratory partners with a 3rd party safety consultant who serves as the chairman of the Israeli Biosafety Association (IBSA) and a member of the American Biosafety Association (ABSA). Regular communication with our safety consultant and annual safety audits are conducted.

All laboratory personnel must complete regular safety training before entering the laboratory. Furthermore, team members receive necessary updates through handouts and posters in all rooms. Our laboratories are equipped with essential safety equipment, such as protective gloves, first aid kits, and appropriate signage on laboratory doors.

Our safety standards align with the US National Institute of Health (NIH) and World Health Organization (WHO) guidelines, as well as all local regulations.

The background features a large, semi-transparent watermark of the word 'ENVIRONNEMENT' in a light blue, sans-serif font. Overlaid on this are several white, thin lines forming a network or web-like structure, with some nodes highlighted in light blue. A solid white horizontal line is positioned above the main title.

ENVIRONNEMENT

Our Environmental Management

At Quris-AI, we take responsibility for our environmental impact. We recognize the pharmaceutical industry's potential environmental risks and contributions to climate change, as drug production processes often involve toxic chemicals and generate biohazardous waste. We work to reduce our environmental footprint by promoting energy efficiency and minimizing waste where possible. As pioneers in AI-based drug development, we help decrease resource inefficiencies in the pharmaceutical industry.



Energy management

As an international company, we acknowledge our responsibility to mitigate our climate impact. In 2022, we were unable to calculate our precise energy consumption and GHG footprint due to a flat-rate billing system that did not provide consumption data. However, starting in 2023, we have ensured our ability to measure our HQ energy use and plan to monitor our energy consumption and calculate our GHG footprint in 2023 and beyond. This will allow us to better understand our consumption and set future reduction targets.

We focus on enhancing energy efficiency in our offices and laboratories. Our efficient office practices include using LED lighting throughout all offices. Moreover, our air conditioning unit automatically shuts off daily to conserve resources. We emphasize reducing our environmental footprint and promoting energy-saving practices.

“Climate change is the single biggest health threat facing humanity, and health professionals worldwide are already responding to the health harms caused by this unfolding crisis.”

[World Health Organization](#)

Waste management

We are dedicated to the responsible handling of both regular and biohazardous waste. Our waste management strategy includes sorting waste generated in our laboratories into three categories:

- General waste
- Biological waste
- Paper and cardboard

Our top priority is to prevent biohazardous waste from contaminating the environment. To enhance our biological waste management, we collaborate with a third-party waste disposal service specializing in the sterilization and disposal of such waste. Our waste management provider is ISO 14001 and ISO 9001 certified, ensuring responsible waste handling. Biohazardous waste is collected from our laboratory twice a month for safe disposal, adhering to all local and standard regulations for secure waste processing.

We are committed to minimizing our environmental footprint and raising awareness of our environmental impact. We encourage employees to reduce waste in offices and laboratories and be mindful of their individual footprints. In line with our sustainable values, we have limited the use of single-use plates and cups at our offices.

Water use

We monitor water usage at our facilities and aim to reduce consumption wherever possible. Our flood detector helps conserve resources by detecting the presence of water in the event of leaks. Currently, water is not a material environmental issue for Quris-AI, as our operations involve minimal water usage, primarily within our offices. As our company operations expand, we will continue to evaluate our water footprint and assess its materiality for our business.



GOVERNANCE & ETHICS

Ethical Governance

Quris-AI recognizes the importance of effective governance for a company's health and long-term success. Our [Code of Conduct](#) sets expectations for consistent ethical performance and behavior across the company. All employees receive information on the 'Code of Conduct' during onboarding, and management emphasizes the importance of ethical performance while promoting a culture of open communication and transparency.

Our Code of Conduct is available on our [policy section](#) and addresses ethical issues such as:

- Workplace Decorum
- Conflict of Interest
- Anti-Corruption
- Whistleblower Protection

Our ESG Policies

Our governance policies are developed and approved through a participatory process that involves managers from different departments in dialogue with company leadership. Our current company [policies](#) include:

- Code of Conduct
- Non-discrimination and DEI Policy
- Regulations for the Prevention of Sexual Harassment
- Data Privacy Policy
- Supplier Code of Conduct

As our company grows, we will continue to assess the relevance of additional ethical training for our employees, ensuring alignment with ethical best practices.



Conflict Minerals

Quris-AI is committed to responsible sourcing. Our primary suppliers refrain from using conflict minerals, RoHS substances, and other harmful processes or formulations in their ingredients.

Ethical Marketing Practices

We are steadfast in our commitment to ethical marketing practices and ensure that all claims made in our processes undergo a thorough scientific review. This allows us to confidently stand behind our assertions.



ABOUT THIS REVIEW

About this Review

This is Quris-AI's first UNSDG Impact & ESG Review and contains an overview of our related impacts and initiatives during the reporting period of January 2022 - May 2023. The scope of this review includes efforts at our Israel-based headquarters and our US employees. Moving forward, we intend to report on our ESG performance annually, offering transparent and succinct data on our performance while actively promoting dialogue about potential improvements over time.



Statement from Good Vision (Grant Thornton Group)

Good Vision of the Fahn Kanne & Co. Grant Thornton Group supported Quris-AI in the writing of this report. Good Vision is a member organization of the SASB Consultants Content Program and GRI Gold Community which work to empower businesses, corporations and decision makers everywhere to act towards a more sustainable economy and future through ESG initiatives and stewardship. Good Vision is a recognized leader in sustainability advising, ESG disclosure and the UNSDG and is a member of Grant Thornton, the world's sixth largest accounting firm.



CONSULTANT
CONTENT
PROGRAM

Contact Us

Should you have any inquiries or feedback regarding this report, please reach out to:

Geva Feller
Business Development Lead
geva@quris.ai

Nitai Agnon
ESG Lead
nitai@quris.ai

Nogah Seidemann
Sustainability Services Advisor at GoodVision CSR
(Grant Thornton Group)
Nogah.Seidemann@goodvision.co.il

SASB INDEX

TOPIC	ACCOUNTING METRIC	CODE	DISCLOSURE
Access to Medicines	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	HC-BP-240a.1	See Drug Development Focusing on Rare Diseases
	List of Products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	HC-BP-240a.2	N/A
Employee Recruitment, Development, & Retention	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	HC-BP-330a.1	See Employee Development and Training
	1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	HC-BP-330a.2	N/A
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit programs for integrity of supply chain and ingredients	HC-BP-430a.1	N/A
	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality	HC-MS-430a.1	N/A
	Description of efforts to maintain traceability within the distribution chain	HC-MS-430a.2	Code of Conduct
	Description of the management of risks associated with the use of critical materials	HC-MS-430a.3	N/A

TOPIC	ACCOUNTING METRIC	CODE	DISCLOSURE
Product Design and Lifecycle Management	Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products	HC-MS-410a.1	See Commitment to Patients & Community
	Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies	HC-MS-410A.2	N/A
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	HC-BP-270a.2	N/A
	Description of code of ethics governing promotion of off-label use of products	HC-BP-330a.2	N/A
Product Safety	Number of recalls issued, total units recalled	HC-MS-250a.1	N/A
	List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database	HC-MS-250a.2	N/A
	Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience	HC-MS-250a.3	N/A
	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	HC-MS-250a.4	N/A

TOPIC	ACCOUNTING METRIC	CODE	DISCLOSURE
Drug Safety	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	HC-BP-250a.1	N/A
	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	HC-BP-250a.2	N/A
	Total amount of product accepted for takeback, reuse, or disposal	HC-BP-250a.4	N/A
	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	HC-BP-250a.5	N/A
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	HC-BP-510a.1	N/A
	Description of code of ethics governing interactions with healthcare professionals	HC-BP-510a.2	WIP



Quris-AI Tel Aviv

6 HaNatsiv St., Tel-Aviv, Israel
contact@quris.ai

Quris-AI Boston

38 Wareham St., Boston, MA
contact@quris.ai